At this point, I'll be quite happy to never hear or read the word "Achillion" again, as my former positive calls on Achillion Pharmaceuticals (ACHN)
just keep looking worse and worse. With the company's post-Friday close
clinical update, it's very difficult to argue that there's enough value
left in this name to bother with it even further. I have no doubt that
there will be a "never say die" contingent that wants to stick with this
name, and I suppose I can't completely rule out the possibility that
the next drug combo will work, but the combination of weak data,
questionable reporting of that data, and the emerging competitive
landscape just makes it too hard to look at this name even as a serious
dumpster-diving candidate.
Please follow the link to continue:
Achillion Is Burnt Toast
No comments:
Post a Comment